ArticleWorld journal of urology2023
A self-supervised vision transformer to predict survival from histopathology in renal cell carcinoma.
Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Deep-learning-based artificial intelligence approaches for grading and progression prediction of clear cell renal cell carcinoma.iScience · 2026Article
- Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.NPJ digital medicine · 2026Article
- Intelligent identification of medical and veterinary intracellular protozoa by using self-supervised learning.Parasites & vectors · 2026Article
- Deciphering the mechanistic landscape of immune checkpoint blockade in ccRCC: from molecular drivers to therapeutic responses.Frontiers in immunology · 2026Review
- Artificial Intelligence in Nephrology: From Early Detection to Clinical Management of Kidney Diseases.Bioengineering (Basel, Switzerland) · 2025Review
- Deep learning based on ultrasound images to predict platinum resistance in patients with epithelial ovarian cancer.Biomedical engineering online · 2025Article
- A novel rotation and scale-invariant deep learning framework leveraging conical transformers for precise differentiation between meningioma and solitary fibrous tumor.Journal of pathology informatics · 2025Article
- Multi-Classification of Skin Lesion Images Including Mpox Disease Using Transformer-Based Deep Learning Architectures.Diagnostics (Basel, Switzerland) · 2025Article
- Explainable Deep Learning for Glaucomatous Visual Field Prediction: Artifact Correction Enhances Transformer Models.Translational vision science & technology · 2025Article
- Deep learning-based analysis of EGFR mutation prevalence in lung adenocarcinoma H&E whole slide images.The journal of pathology. Clinical research · 2024Article
- Equipping computational pathology systems with artifact processing pipelines: a showcase for computation and performance trade-offs.BMC medical informatics and decision making · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeTo develop and validate an interpretable deep learning model to predict overall and disease-specific survival (OS/DSS) in clear cell renal cell carcinoma (ccRCC).
methodsDigitised haematoxylin and eosin-stained slides from The Cancer Genome Atlas were used as a training set for a vision transformer (ViT) to extract image features with a self-supervised model called DINO (self-distillation with no labels). Extracted features were used in Cox regression models to prognosticate OS and DSS. Kaplan-Meier for univariable evaluation and Cox regression analyses for multivariable evaluation of the DINO-ViT risk groups were performed for prediction of OS and DSS. For validation, a cohort from a tertiary care centre was used.
resultsA significant risk stratification was achieved in univariable analysis for OS and DSS in the training (n = 443, log rank test, p < 0.01) and validation set (n = 266, p < 0.01). In multivariable analysis, including age, metastatic status, tumour size and grading, the DINO-ViT risk stratification was a significant predictor for OS (hazard ratio [HR] 3.03; 95%-confidence interval [95%-CI] 2.11-4.35; p < 0.01) and DSS (HR 4.90; 95%-CI 2.78-8.64; p < 0.01) in the training set but only for DSS in the validation set (HR 2.31; 95%-CI 1.15-4.65; p = 0.02). DINO-ViT visualisation showed that features were mainly extracted from nuclei, cytoplasm, and peritumoural stroma, demonstrating good interpretability.
conclusionThe DINO-ViT can identify high-risk patients using histological images of ccRCC. This model might improve individual risk-adapted renal cancer therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.